Vistara single-gene non-invasive prenatal test

Vistara facilitates early diagnosis for skeletal, cardiac, and neurological disorders

Panorama non-invasive prenatal test




Vistara single-gene non-invasive prenatal test




Anora miscarriage




Horizon advanced carrier screening



What is Vistara?

Vistara is a non-invasive prenatal test (NIPT) which screens cell-free DNA (cfDNA) for monogenic mutations.

Vistara screens 30 genes involved in a number of severe diseases including: skeletal diseases, cardiovascular diseases and neurological diseases.

Conditions screened by Vistara have a combined incidence of 1 in 600 – higher than that of Down syndrome. Diseases meet at least one of the following criteria:

• Causes cognitive disabilities

• Requires surgical or medical interventions

• It affects the quality of life


Vistara has a combined analytical sensitivity and specificity of >99% in validation studies and no known false positives in commercial experience.


Vistara identifies risk for single-gene disorders that may have otherwise gone undetected prenatally.

• No other non-invasive prenatal screening (NIPT) test can identify these diseases, and invasive tests do not guarantee a diagnosis

• Family history is usually not a good indicator of risk for these diseases which are, in most cases, caused by de novo mutations

• Ultrasound investigations are not reliable indicators for these diseases

Prenatal screening with Vistara can lead to improved delivery management and targeted neonatal care



Early testing with Vistara allows patients to be guided toward to the maternal-fetal morphology specialist or other specialists for specific tests, as follows: fetal echocardiograms, NMR and targeted anatomical evaluations.




Prenatal fetal diagnosis allows doctors and patients to plan the child delivery in specialized clinics which are properly equipped in order to ensure immediate assessment of the condition of the baby and administration of the necessary treatment.




Understanding these complex genetic conditions before birth allows families to plan their resources, ask more questions and anticipate future needs.


Vistara identifies risk for single-gene disorders that may have otherwise gone undetected prenatally


Ultrasound identification of the diseases

A significant number of diseases can’t be detected through ultrasound

Where there is no indication of a fetal disease during the pregnancy, doctors and patients are not prepared for the birth of an affected child.

Very often, ultrasound findings occur at advanced pregnancy ages

These diseases can be identified only in third pregnancy quarter when confirmation through an invasive test can lead to spontaneous abortion.

Many diseases have non-specific identifiable ultrasound features

Non-specific findings such as nucal translucency and cardiac malformations may have a variety of causes.


Copyright by AMS 2018. All rights reserved.